Dummit E S, Klein R G, Tancer N K, Asche B, Martin J
New York State Psychiatric Institute, Columbia University, New York, USA.
J Am Acad Child Adolesc Psychiatry. 1996 May;35(5):615-21. doi: 10.1097/00004583-199605000-00016.
A pilot study was designed to evaluate the safety and efficacy of fluoxetine treatment for children with selective mutism (elective mutism in DSM-III-R).
Twenty-one children (mean age 8.2 years, range 5 through 14) participated in a 9-week open trial of fluoxetine in graduated doses (mean end dose 28.1 mg, range 10 to 60 mg) with systematic baseline and outcome evaluations and weekly clinical assessment.
All 21 children met DSM-III-R and DSM-IV criteria for anxiety disorders. After fluoxetine treatment, 76% were improved, with diminished anxiety and increased speech in public settings, including school. Improvement at week 9 was inversely correlated with age.
Persistent selective mutism presenting with comorbid anxiety disorders may respond to fluoxetine treatment.
设计一项初步研究以评估氟西汀治疗选择性缄默症（《精神疾病诊断与统计手册第三版修订本》中的选择性缄默症）儿童的安全性和有效性。
21名儿童（平均年龄8.2岁，范围为5至14岁）参与了一项为期9周的氟西汀开放试验，采用逐渐递增剂量（平均最终剂量28.1毫克，范围为10至60毫克），并进行系统的基线和结果评估以及每周的临床评估。
所有21名儿童均符合《精神疾病诊断与统计手册第三版修订本》和《精神疾病诊断与统计手册第四版》中焦虑症的标准。经过氟西汀治疗后，76%的儿童病情有所改善，焦虑减轻，在包括学校在内的公共场所的言语交流增加。第9周时的改善情况与年龄呈负相关。
伴有共病焦虑症的持续性选择性缄默症可能对氟西汀治疗有反应。
